Pharma Giants Harness AI to Combat Counterfeit Drugs

Pharma giants and civil‑society groups are taking AI‑powered monitoring systems to the next level in the fight against counterfeit products.

Digital Surveillance & AI: The New Counterfeit Foe

During the "Intellectual Property Crimes and Public Health Workshop" co‑organized by the Turkish National Police and Anadolu Agency, AbbVie's European Regional Director Gert‑Jan Van Diest highlighted that online sales channels are the main conduit for counterfeit goods. The company disclosed that AI‑driven monitoring tools have boosted its data‑collection capacity by 45%.

Key Statements from Industry Leaders

■Kenvue's Global Brand Protection Manager Muhammed Taha warned that counterfeit items are increasingly masked by AI‑generated images, making detection far more challenging.

■Merck KGaA's Global Health Sector Investigations Head Janina Seiler emphasized the critical role of information sharing in dismantling counterfeit networks and noted ongoing intelligence exchanges via the REACT platform.

■Novartis's European Counterfeit Medicines Combat Manager Lucy Hambloch stressed that verification of packaging and expiry dates, conducted jointly with law‑enforcement, is essential to curb fake drug distribution.

Hard Data & Collaboration Dynamics

■AI‑driven surveillance: Achieves 30% faster counterfeit detection.

■Reporting channels: Tips from employees, physicians, and aesthetic clinics have risen by 25%.

■Joint operations: In Romania and Turkey, seized counterfeit medicines saw 60% pass authenticity checks.

■Platform integration: REACT updates data exchanges between companies and authorities three times per week.

The proliferation of counterfeit goods across digital ecosystems, especially with AI‑crafted fake visuals, is turning the threat landscape increasingly complex. Market participants must treat AI‑based monitoring and real‑time data sharing as strategic imperatives; failure to do so will amplify brand erosion and regulatory penalties. This evolution will reshape both internal security spend and sector‑wide compliance costs.